Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
30th Annual Meeting of the ISCP
Author(s): Daryl Dakay , Marion Patricio Added: 2 months ago

Prevention & Chronic Conditions

Heart Failure
Maternal Cardiac Function in Pregnancies With Metabolic Disorders
Author(s): Deesha Patel , Makrina D Savvidou Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions
Left Main Disease: The Last Frontier for Medical Therapy in Stable CAD?
Author(s): Armin Arbab-Zadeh , Michelle Graham , Hector M Garcia-Garcia , et al Added: 9 months ago

Intervention

Prevention & Chronic Conditions
Left Atrium Role in Secondary Mitral Regurgitation
Author(s): Markos Koukos , Yannis Dimitroglou , Dimitrios Tsartsalis , et al Added: 2 years ago

Vascular Disease and Surgery

Imaging & Diagnostics
Non-invasive Coronary Functional Tests in ANOCA
Author(s): Nello Cambise , Angelo Giuseppe Marino , Fabio De Benedetto , et al Added: 4 months ago

Imaging & Diagnostics

Prevention & Chronic Conditions
TCT 24: The EVOLVED Trial
Author(s): Marc Dweck Added: 1 year ago
TCT Conference 2024 - Clinical outcomes of early intervention in patients with asymptomatic aortic stenosis (AS) did not impact the composite primary outcome of all cause mortality and unplanned AS related hospitalisation.Dr Marc Dweck (University of Edinburgh, Edinburgh, UK) joins us in this short interview filmed onsite at TCT Conference to discuss the findings from EVOLVED (NCT03094143;… View more

Imaging & Diagnostics

Intervention
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 1 year ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Kidney Metabolic

Heart Failure
TCT 2025: 10-Year Mortality in NOBLE: PCI vs CABG for Left Main Disease
Author(s): Evald Høj Christiansen Added: 7 months ago
TCT 2025 - 10-year findings from NOBLE showed no safety concerns for percutaneous coronary intervention (PCI) compared to coronary artery bypass surgery (CABG) for the treatment of left main coronary artery (LMCA) disease.Dr Evald Høj Christiansen (Aarhus University Hospital, Aarhus, DK) joins us to share the 10-year mortality findings from the NOBLE trial, investigating PCI vs CABG in LMCA… View more

Intervention

Prevention & Chronic Conditions
Kidney Function Trajectories Before and After HF Hospitalisation
Author(s): Nicolas Girerd Added: 1 year ago
ESC HF 25 - Real-world findings suggest kidney function decline could precede heart failure events by up to a year.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses real-world findings from pooled trials EPHESUS, EMPHASIS-HF and BARCELONA. The study investigated if longitudinal changes in kidney function could help identify patients with HFrEF at a higher risk of… View more

Cardiovascular Kidney Metabolic

Heart Failure
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status
Author(s): Mikhail Kosiborod Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic